Back to Search
Start Over
Serial measurement of galectin-3 in patients with chronic heart failure: results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study
- Source :
- European journal of heart failure. 15(10)
- Publication Year :
- 2013
-
Abstract
- Aims Galectin-3 is a prognostic heart failure (HF) biomarker that may mediate cardiac fibrosis. We examined the value of serial galectin-3 measurement for prognosis and response to therapy in chronic HF. Methods and results A total of 151 subjects with LV systolic dysfunction (LVSD) were followed through 908 visits over 10 ± 3 months. The amount of time spent with a galectin-3 level ≤ 20.0 ng/mL and changes between baseline and subsequent values were considered across visits, and used to assess risk for adverse cardiovascular (CV) events and associations with LV remodelling. Medication effects on galectin-3 were examined. Median galectin-3 values at baseline, 3 months, and 6 months were higher in patients with CV events (21.7 vs. 18.4 ng/mL, P = 0.03; 21.7 vs. 16.5 ng/mL, P = 0.03; 23.2 vs. 16.0 ng/mL, P = 0.007). Galectin-3 concentration changed in 35.2% of subjects during study procedures; time spent at ≤ 20.0 ng/mL was significantly associated with a lower rate of CV events, independently predicted fewer CV events even adjusted for relevant variables including study allocation, NT-proBNP, and renal function [odds ratio (OR) = 0.90; P = 0.05], and predicted increase in LV ejection fraction (OR = 1.20; P = 0.04). Serial galectin-3 measurement at 6 months added prognostic value beyond the baseline level (P = 0.02). There were no significant effects of medications on galectin-3 levels. Conclusion In chronic HF due to LVSD, serial galectin-3 measurement adds incremental prognostic information and predicts LV remodelling. In this study, HF therapies had no clear effects on galectin-3 levels.
- Subjects :
- Adult
Male
medicine.medical_specialty
Cardiac fibrosis
Galectin 3
Galectins
Heart Ventricles
Adrenergic beta-Antagonists
Renal function
Angiotensin-Converting Enzyme Inhibitors
Internal medicine
Natriuretic Peptide, Brain
medicine
Odds Ratio
Humans
Ventricular remodeling
Diuretics
Aged
Aged, 80 and over
Heart Failure
Ejection fraction
Ventricular Remodeling
business.industry
Odds ratio
Blood Proteins
Middle Aged
medicine.disease
Prognosis
Peptide Fragments
Treatment Outcome
Galectin-3
Echocardiography
Heart failure
Chronic Disease
Cardiology
Physical therapy
Disease Progression
Biomarker (medicine)
Female
Cardiology and Cardiovascular Medicine
business
Biomarkers
Subjects
Details
- ISSN :
- 18790844
- Volume :
- 15
- Issue :
- 10
- Database :
- OpenAIRE
- Journal :
- European journal of heart failure
- Accession number :
- edsair.doi.dedup.....62f37beb0b65f58b217884ae5ef1d746